ESMO Clinical Practice Guidelines for PCa treatments 2015

The European Society for Medical Oncology published their updated Clinical Practice Guidelines for for PCa treatments 2015.

The updated ESMO Clinical Practice Guidelines on prostate cancer provide information on the current management of prostate cancer including recommendations for screening and diagnosis, along with stage-matched therapeutic strategies.

ESMO recommendations include:

• Patients with intermediate- or high-risk disease should have nodal staging using computed tomography (CT), MRI, choline positron emission tomography/CT (PET/CT) or pelvic nodal dissection. 

• Patients with intermediate- or high-risk disease should be staged for metastases using technetium bone scan and thoraco-abdominal CT scan or whole-body MRI or choline PET/CT

• Watchful waiting with delayed hormone therapy is an option for men with low-risk disease.

• Watchful waiting with delayed hormone therapy is an option for men with localised or locally advanced disease who are not suitable for, or unwilling to have, radical treatment. 

• Active surveillance is an option for men with low-risk disease.

• RP or radiotherapy (external beam or brachytherapy) are options for men with low- or intermediate-risk disease.

• Primary ADT alone is not recommended as standard initial treatment of non-metastatic disease.

• Options for patients with high-risk or locally advanced prostate cancer include external beam RT plus hormone treatment or RP plus pelvic lymphadenectomy. 

For full review and recommendations visit ESMO website below:

http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate

Take care 

Allen Lai